Column 16. What Is the Actual Status of Radiotherapy (External Beam Radiotherapy and 131I MIBG Therapy)?
Evidence is lacking for external beam radiotherapy for medullary carcinoma, and its significance remains unknown. A therapy using 131I MIGB, which is a norepinephrine analogue, can be performed domestically when an individual patient imports 131I MIGB for his/her own use. It is impossible to perform radioimmunotherapy using Y-90-DOTATOC, a somatostatin analogue, and an anti-CEA antibody in Japan, although some reports have been published in Western countries.
KeywordsNeuroendocrine Tumor External Beam Radiotherapy Medullary Thyroid Carcinoma Medullary Carcinoma Uptake MIBG
- 2.Nakajo M, Yoshinaga K, Oriuchi N et al (2008) (Text in Japanese) Kakuigaku 45:1–40(Suppl) (Others)Google Scholar
- 6.Tsukamoto E, Yoshinaga K, Tamaki N (2001) (Text in Japanese) Eizo Joho Med 33:1076–1080 (CaseR)Google Scholar
- 10.Chatal JF, Campion L, Kraeber-Bodéré F et al (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24:1705–1711 (RS)PubMedCrossRefGoogle Scholar